Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toralf Roch

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Current Research in Translational Medicine|February 22, 2022
Early prediction of renal graft function: Analysis of a multi-center, multi-level data setArturo Blazquez-Navarro, Chris Bauer, Nicole Wittenbrink, et al.
Kidney International|September 14, 2022
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorderConstantin J Thieme, Malissa Schulz, Patrizia Wehler, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|August 27, 2021
Risk factors for Epstein-Barr virus reactivation after renal transplantation: Results of a large, multi-centre studyArturo Blazquez-Navarro, Chantip Dang-Heine, Patrizia Wehler, et al.
Kidney International|July 17, 2021
Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patientsArturo Blazquez-Navarro, Lema Safi, Toni L Meister, et al.
Molecular Therapy. Methods & Clinical Development|March 7, 2022
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patientsLena Peter, Désirée Jacqueline Wendering, Stephan Schlickeiser, et al.
Kidney International|October 7, 2021
Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal diseaseUlrik Stervbo, Arturo Blazquez-Navarro, Elena Vidal Blanco, et al.
Allergy|March 25, 2021
Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunityConstantin J Thieme, Mohamed Abou-El-Enein, Enrico Fritsche, et al.
Journal of the American Society of Nephrology : JASN|October 30, 2021
Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2Constantin J Thieme, Arturo Blazquez-Navarro, Lema Safi, et al.
Science Translational Medicine|January 14, 2021
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancerTino Vollmer, Stephan Schlickeiser, Leila Amini, et al.
Frontiers in Immunology|February 11, 2022
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA VaccinationKrystallenia Paniskaki, Moritz Anft, Toni L Meister, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Current Research in Translational Medicine|February 22, 2022
Early prediction of renal graft function: Analysis of a multi-center, multi-level data setArturo Blazquez-Navarro, Chris Bauer, Nicole Wittenbrink, et al.
Kidney International|September 14, 2022
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorderConstantin J Thieme, Malissa Schulz, Patrizia Wehler, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|August 27, 2021
Risk factors for Epstein-Barr virus reactivation after renal transplantation: Results of a large, multi-centre studyArturo Blazquez-Navarro, Chantip Dang-Heine, Patrizia Wehler, et al.
Kidney International|July 17, 2021
Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patientsArturo Blazquez-Navarro, Lema Safi, Toni L Meister, et al.
Molecular Therapy. Methods & Clinical Development|March 7, 2022
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patientsLena Peter, Désirée Jacqueline Wendering, Stephan Schlickeiser, et al.
Kidney International|October 7, 2021
Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal diseaseUlrik Stervbo, Arturo Blazquez-Navarro, Elena Vidal Blanco, et al.
Allergy|March 25, 2021
Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunityConstantin J Thieme, Mohamed Abou-El-Enein, Enrico Fritsche, et al.
Journal of the American Society of Nephrology : JASN|October 30, 2021
Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2Constantin J Thieme, Arturo Blazquez-Navarro, Lema Safi, et al.
Science Translational Medicine|January 14, 2021
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancerTino Vollmer, Stephan Schlickeiser, Leila Amini, et al.
Frontiers in Immunology|February 11, 2022
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA VaccinationKrystallenia Paniskaki, Moritz Anft, Toni L Meister, et al.
Pageof 8